Where is Heartseed located?

Heartseed is headquartered in Shinjuku City, Japan.

How many employees does Heartseed have?

As of Aug 31, 2026, the latest employee count at Heartseed is 20.

Is Heartseed a funded company?

Heartseed is a funded company, having raised a total of $76.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of Heartseed?

Heartseed's latest funding was a $***** Series D round on May 25, 2023, with participation from 9 investors. Its primary sector is Cardiac and Vascular Disorders. In Japan, the Cardiac and Vascular Disorders sector has seen $17M in funding in 2026 to date.

Where does Heartseed rank among its competitors?

Heartseed ranks 17th amongst 83 active competitors, of which 27 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Secretome Therapeutics, which secured $30M in May, 2026.

Who are the top competitors of Heartseed?

Heartseed's top competitors include AskBio, Humacyte and AxoGen. Among them, Secretome Therapeutics secured the most recent funding round in May, 2026.

Heartseed - 2026 Company Profile, Team, Funding & Competitors

Company Details

Heartseed is developing myocardial regenerative medicine for treating heart diseases. The company is developing regenerative medicines by using human iPS cells. The lead product HS-001 allogeneic iPS cell-derived regenerated myocardium for the treatment of heart failure

Website: heartseed.jp
Email ID: *****@heartseed.jp

Key Metrics

Founded Year

2015

Location

Shinjuku City, Japan

Stage

Public

Total Funding

$76.7M in 5 rounds

Latest Funding Round

Series D, May 25, 2023, $*****

Investors

SMBC Venture Capital & 19 more

Ranked

17^th among 83 active competitors

Employee Count

20 as on Aug 31, 2026

Similar Companies

AskBio & 90 more

Exit Details

Public

View Heartseed's full profile

Heartseed got listed on Jul 30, 2024.

Click here to take a look at Heartseed's IPO in detail

Heartseed has raised a total funding of $76.7M over 5 rounds. Its latest funding round was a Series D round on May 25, 2023 for $*****. 9 investors participated in its latest round. Heartseed has 19 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Heartseed:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 25, 2023	6080767	Series D	6303802	8336971	4304916	6712761
Jun 11, 2021	9338256	Series C	6415356	2630299	9859285	SMBC Capital Markets & 3 more
Mar 10, 2020	9112988	Series B	8151001	8392218	MEDIPAL	2893113

Access funding benchmarks and valuations. Sign up today!

View details of Heartseed's funding rounds and investors

The founders of Heartseed is Keiichi Fukuda. Keiichi Fukuda is the CEO of Heartseed.

Here are the details of Heartseed's key team members:

Keiichi Fukuda: Founder & CEO of Heartseed.
Contact Info: 1 email address

View details of Heartseed's Founder profiles and Board Members

Heartseed's employee count trend

Heartseed has 20 employees as of Aug 26. Here is Heartseed's employee count trend over the years:

Uncover Heartseed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Heartseed include AskBio, Humacyte and AxoGen. Here is the list of Top 10 competitors of Heartseed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
2nd	Humacyte 2004, Durham (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Fresenius Medical Care ... & 15 others	66/100
3rd	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 10 others	65/100
4th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
5th	CUTISS 2017, Zurich (Switzerland), Series C	Company developing personalized skin tissue therapeutics for skin defect treatments	$157M	Cherry Bay Capital Group, Rode Kruis Ziekenhuis ... & 15 others	62/100
6th	Nuevocor 2021, Singapore (Singapore), Series B	Developer of genetic medicines for treating rare heart muscle conditions	$80.6M	Kurma Partners, Boehringer Ingelheim Venture Fund ... & 7 others	62/100
7th	AnaCardio 2017, Sweden, Series A	Developer of drugs for heart failure treatment	$36.5M	Industrifonden, Pureos Bioventures & 9 others	61/100
8th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	61/100
9th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 10 others	59/100
10th	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
17th	Heartseed 2015, Shinjuku City (Japan), Public	Developer of myocardial regenerative medicine for treating heart diseases	$76.7M	Sumitomo Mitsui Trust Holdings, SBI Group ... & 18 others	47/100